In focus this morning are major financial institutions' quarterly results and a slew of upcoming economic data.
Investors can still find some compelling valuations among large-cap drug companies even as major stock indices hit new highs.
Amgen, Celgene and Pharmacyclics see short interest drop recently.
Even as medical insurers react positively to news, other economically sensitive sectors are under attack.
If the market's recent rise has you nervous, switching to more defensive investments may be a better course of action than fleeing the market altogether.
Some major branded drugs will lose patent protection, and market share along with it, this year.
Congrats, market, on 8 straight up days. But 9? The last time we had a winning streak like that was last century.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.